The Biggest Challenges In Autologous Cell Therapy Manufacturing
Source: Entegris, Inc.
From the need for automation in manufacturing to the sourcing of tissue from a specific patient, Omkar Kowlaker, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte and Donna Rill, Chief Technology Officer at Triumvira Immunologics, share tremendous detail around the challenges facing autologous cell therapy manufacturing.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Entegris, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more